Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer

On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co‘s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

The decision is based on global Phase 2 TRANSCEND FL study results.

Also Read: Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy ...